Dr. Chu has served as a member of our board of directors since August 2025. Since 2020, Dr. Chu has been a Partner of Lightspeed Venture Partners, where she leads the Biotech Practice and co-heads the Healthcare Sector. She currently serves on the board of directors of Antares Therapeutics, Diagonal Therapeutics, Alpha-9 Oncology, Seismic Therapeutics, Triana Therapeutics, Enlaza Therapeutics, Protego BioPharma, and Zag Bio, and has previously served on the board of directors of private and public companies, including Scorpion Therapeutics (acquired by Eli Lilly & Co.), HilleVax (Nasdaq: HLVX), Tizona Therapeutics, Inc. (acquired by Gilead Sciences, Inc.), Trishula Therapeutics (partnered with AbbVie Inc.), IFM Therapeutics, Inc. (acquired by Bristol Myers Squibb), IFM Tre (acquired by Novartis AG), IFM Due (acquired by Novartis AG), IFM Quattro, and SFJ Pharmaceuticals. Dr. Chu also led R&D strategy across all therapeutic areas, as well as business development in immuno-oncology and hepatitis B virus at Gilead during the launch of their cure for hepatitis C virus. Dr. Chu holds an M.D. and a Ph.D. in Biochemistry and Biophysics from the University of California, San Francisco and a B.A. in Molecular Biology from Princeton University, where she serves as Co-Chair for Princeton ASC. She is also a member of the Scientific Advisory Board for BioCentury.
What is Shelley Chu's net worth?
The estimated net worth of Shelley Chu is at least $191.44 thousand as of May 11th, 2026. Chu owns 11,111 shares of Odyssey Therapeutics stock worth more than $191,443 as of June 9th. This net worth estimate does not reflect any other assets that Chu may own. Learn More about Shelley Chu's net worth.
Has Shelley Chu been buying or selling shares of Odyssey Therapeutics?
Over the course of the past ninety days, Shelley Chu has bought $199,998.00 in Odyssey Therapeutics stock. Most recently, on Monday, May 11th, Shelley Chu bought 11,111 shares of Odyssey Therapeutics stock. The stock was acquired at an average cost of $18.00 per share, with a total value of $199,998.00. Following the completion of the transaction, the director now directly owns 11,111 shares of the company's stock, valued at $199,998. Learn More on Shelley Chu's trading history.
Who are Odyssey Therapeutics' active insiders?
Are insiders buying or selling shares of Odyssey Therapeutics?
During the last year, Odyssey Therapeutics insiders bought shares 7 times. They purchased a total of 4,183,777 shares worth more than $75,319,986.00. During the last year, insiders at the sold shares 1 times. They sold a total of 1,780 shares worth more than $32,040.00. The most recent insider tranaction occured on May, 11th when Director Nan (Ln) Li bought 1,111,111 shares worth more than $19,999,998.00.
Learn More about insider trades at Odyssey Therapeutics. Information on this page was last updated on 5/11/2026.
